These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1894582)

  • 21. The role of interleukin-2 in cancer immunotherapy.
    Eberlein TJ; Schoof DD
    Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quality control of biological therapy in patients with tumors].
    Zhang S
    Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):483-4. PubMed ID: 9275493
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
    Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphokine activated killer cells: a new approach to immunotherapy of cancer.
    Semenzato G
    Leukemia; 1990 Feb; 4(2):71-80. PubMed ID: 2406518
    [No Abstract]   [Full Text] [Related]  

  • 26. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LAK cells in cancer therapy--European results.
    Sibinga CT
    Prog Clin Biol Res; 1990; 337():439-41. PubMed ID: 2191334
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
    Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract]   [Full Text] [Related]  

  • 29. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 30. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LAK cell therapy--clinical studies and future potential.
    Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
    Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
    Kim S; Haas GP; Hillman GG
    Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
    Osanto S; Brand A; van Rood JJ; Cleton FJ
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758
    [No Abstract]   [Full Text] [Related]  

  • 35. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo.
    Berthold F; Himmelmann U; Pohl U
    Prog Clin Biol Res; 1991; 366():417-24. PubMed ID: 1906185
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of IL-2 in gene therapy.
    Dalgleish AG
    Gene Ther; 1994 Mar; 1(2):83-7. PubMed ID: 7584072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 39. New perspectives in immunotherapy of leukemia.
    Lotzová E
    Immunol Ser; 1994; 61():231-8. PubMed ID: 8011747
    [No Abstract]   [Full Text] [Related]  

  • 40. Rationale and therapeutic basis for patients receiving recombinant interleukin-2.
    Dudjak LA
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):3-7. PubMed ID: 8210792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.